Melanotan I

Melanotan I is a compound with two distinct lives. Its regulatory life belongs to afamelanotide — a 16 mg biodegradable subcutaneous implant marketed as Scenesse by the Australian company Clinuvel Pharmaceuticals. Scenesse has an EMA authorisation dating to 2014 and an FDA approval dating to 2019-10-08, both for the same rare-disease indication: reduction of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), a genetic disorder in which sunlight triggers severe painful skin reactions. In that setting the compound is the first genuinely disease-modifying therapy and is administered by trained healthcare providers every two months. The grey-market life belongs to 'Melanotan I' as a reconstituted subcutaneous injectable sold through research-supply channels for cosmetic tanning. It is chemically the same molecule. It is regulatorily nothing like the same product.

Chemically, the compound is a linear tridecapeptide analogue of α-MSH with two stabilising substitutions: norleucine at position 4 replaces methionine (removing an oxidation site) and D-phenylalanine at position 7 replaces the natural L-phenylalanine (dramatically increasing resistance to proteolysis). The result is a full-agonist melanocortin peptide with a much longer functional half-life than α-MSH, and — in the Scenesse implant format — a controlled release that produces stable exposure over approximately two months. The peptide's clinical effect is driven principally by MC1R activation on melanocytes, which shifts the pigment they synthesise from lighter red/yellow pheomelanin toward darker, more photoprotective eumelanin. That eumelanin darkening is why the compound tans skin, and it is also why it protects EPP patients from the light that would otherwise burn them.

The EPP evidence base is the reason Scenesse is an approved product. Two phase-3 randomised placebo-controlled trials — CUV029 in Europe and CUV039 in the United States, both reported together in Langendonk et al. NEJM 2015 — demonstrated significant improvements in the amount of time EPP patients could tolerate sunlight without pain. The EMA authorised the product first (2014); the FDA followed in 2019. In both jurisdictions the label is narrow and specific to EPP, and administration is restricted to healthcare providers trained on the implant procedure. Scenesse is not sold for cosmetic use in any jurisdiction.

The grey-market cosmetic use of the compound is a separate story. Because the same peptide sequence can be synthesised by research-supply chemistry, it circulates as 'Melanotan I' lyophilized vials sold for subcutaneous reconstitution. Regulators have issued specific warnings against this use: the UK MHRA has warned that 'Melanotan' products (both I and II) are unlicensed medicines; similar warnings exist from the Norwegian, Irish and Australian regulators. Grey-market use inherits none of the identity, sterility, and long-term safety documentation that support Scenesse in EPP, and its cosmetic goal — sustained cosmetic darkening — is not the goal for which the compound has been safety-evaluated in clinical trials.

Melanotan I is a compound with two distinct lives. Its regulatory life belongs to afamelanotide — a 16 mg biodegradable subcutaneous implant marketed as Scenesse by the Australian company Clinuvel Pharmaceuticals. Scenesse has an EMA authorisation dating to 2014 and an FDA approval dating to 2019-10-08, both for the same rare-disease indication: reduction of phototoxicity in adult patients with erythropoietic protoporphyria (EPP), a genetic disorder in which sunlight triggers severe painful skin reactions. In that setting the compound is the first genuinely disease-modifying therapy and is administered by trained healthcare providers every two months. The grey-market life belongs to 'Melanotan I' as a reconstituted subcutaneous injectable sold through research-supply channels for cosmetic tanning. It is chemically the same molecule. It is regulatorily nothing like the same product.

Chemically, the compound is a linear tridecapeptide analogue of α-MSH with two stabilising substitutions: norleucine at position 4 replaces methionine (removing an oxidation site) and D-phenylalanine at position 7 replaces the natural L-phenylalanine (dramatically increasing resistance to proteolysis). The result is a full-agonist melanocortin peptide with a much longer functional half-life than α-MSH, and — in the Scenesse implant format — a controlled release that produces stable exposure over approximately two months. The peptide's clinical effect is driven principally by MC1R activation on melanocytes, which shifts the pigment they synthesise from lighter red/yellow pheomelanin toward darker, more photoprotective eumelanin. That eumelanin darkening is why the compound tans skin, and it is also why it protects EPP patients from the light that would otherwise burn them.

The EPP evidence base is the reason Scenesse is an approved product. Two phase-3 randomised placebo-controlled trials — CUV029 in Europe and CUV039 in the United States, both reported together in Langendonk et al. NEJM 2015 — demonstrated significant improvements in the amount of time EPP patients could tolerate sunlight without pain. The EMA authorised the product first (2014); the FDA followed in 2019. In both jurisdictions the label is narrow and specific to EPP, and administration is restricted to healthcare providers trained on the implant procedure. Scenesse is not sold for cosmetic use in any jurisdiction.

The grey-market cosmetic use of the compound is a separate story. Because the same peptide sequence can be synthesised by research-supply chemistry, it circulates as 'Melanotan I' lyophilized vials sold for subcutaneous reconstitution. Regulators have issued specific warnings against this use: the UK MHRA has warned that 'Melanotan' products (both I and II) are unlicensed medicines; similar warnings exist from the Norwegian, Irish and Australian regulators. Grey-market use inherits none of the identity, sterility, and long-term safety documentation that support Scenesse in EPP, and its cosmetic goal — sustained cosmetic darkening — is not the goal for which the compound has been safety-evaluated in clinical trials.

The pivotal evidence for Scenesse in EPP comes from CUV029 (European) and CUV039 (US) — two randomised placebo-controlled trials pooled in Langendonk et al. NEJM 2015. Both trials measured pain-free sun-tolerance time as a co-primary endpoint. In CUV039 the median hours of pain-free sun-tolerance were meaningfully greater in the afamelanotide arm than in placebo across the 180-day observation period. Quality-of-life instruments moved in the same direction. The result is unusual in rare-disease drug development — a molecularly targeted therapy for a condition previously without any effective medical option.

Beyond EPP, the compound has been studied in small pilot programmes for vitiligo repigmentation in combination with narrow-band UVB (Grimes et al. 2013 pilot), for Hailey-Hailey disease case series, and for photodynamic-therapy-related phototoxicity. None of those secondary indications has reached the phase-3 evidence bar that supported the EPP approval.

Mechanistic characterisation of the [Nle4, D-Phe7]-α-MSH substitutions was published in the 1980s (Sawyer, Hruby and colleagues), and the compound remains an important reference tool in melanocortin pharmacology. The observation that MC1R activation drives eumelanin synthesis explains both the compound's approved use (photoprotection in EPP) and its grey-market cosmetic use.

Scenesse (afamelanotide) is an approved medicinal product for EPP. The EMA centralised authorisation dates to 2014-12-22; the FDA approval dates to 2019-10-08. TGA (Australia) and Swissmedic (Switzerland) authorisations also exist for the same rare-disease indication. It is a first-in-class treatment for a condition that previously had no effective medical therapy, and Clinuvel has continued post-authorisation studies of the compound in adjacent indications, including vitiligo.

The grey-market cosmetic identity of 'Melanotan I' as a reconstituted injectable exists in parallel to the approved product but shares none of its regulatory documentation. The UK MHRA has issued explicit warnings about 'Melanotan' injectable products (both I and II), and equivalent warnings exist from Norwegian, Irish, and Australian authorities. Cosmetic use of the compound is not a supported clinical framework anywhere.

Melanotan I / afamelanotide is not currently on the WADA prohibited list by name, but athletes should verify current WADA status before using melanocortin peptides, which may attract prohibited-substance scrutiny under the S0 category as non-approved substances for their intended purpose.